To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

And other biotech news brought to you by The Readout.

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

Within the next decade, routine screening and preventive care for Alzheimer's disease could become a reality, say researchers ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...